Pharma RSS Digest - 2026-05-29

Overview

The Friday window carried a limited but clinically substantive set of catalysts, with gastrointestinal oncology dominating the newsflow. Two separate Claudin 18.2-targeting programs advanced their registrational trajectories—one moving into Phase III in gastric cancer, another presenting confirmatory Phase II data in pancreatic cancer—while a dental services partnership signaled continued consolidation activity in healthcare adjacent sectors. The absence of broad market themes and reliance on single-company announcements reflects a light tape environment typical of late-week releases ahead of the ASCO Annual Meeting, where additional GI oncology data is expected next week.

Key Developments

Antengene's ATG-022 Clears Final Regulatory Hurdle for Phase III Launch in CLDN18.2+ Gastric Cancer Antengene received CDE endorsement to initiate the pivotal Phase III CLINCH-3 trial for ATG-022, a Claudin 18.2 antibody-drug conjugate, in patients with CLDN18.2-positive advanced gastric or gastroesophageal junction adenocarcinoma. The Phase I/II CLINCH study supported this decision, demonstrating objective response rates of 46.7% at 1.8 mg/kg and 40.0% at 2.4 mg/kg, with disease control rates exceeding 86% and a differentiated safety profile showing only 19.4% Grade 3 or higher treatment-related adverse events at the lower dose. The randomized, open-label multicenter study will evaluate ATG-022 against investigator's choice, with progression-free survival and overall survival as primary endpoints, and is planned as a multi-regional trial with China as the initial site. The drug previously received Breakthrough Therapy Designation from the CDE, streamlining regulatory communications. Investors should monitor for confirmation of additional countries joining the MRCT and for the first patient enrolled milestone, as these will provide timeline visibility for a potential approval pathway in a setting with limited effective third-line options.

Antengene clinical trial update

Phanes' Spevatamig Posts Competitive Response Rates in Frontline Pancreatic Cancer at ASCO Phanes Therapeutics released updated Phase II results for spevatamig (PT886), an innate immunity enhancer bispecific antibody targeting Claudin 18.2 and CD47, showing a 52.4% objective response rate and 90.5% disease control rate when combined with chemotherapy in frontline metastatic pancreatic ductal adenocarcinoma. Among U.S. patients treated at the 2 mg/kg weekly dose, median progression-free survival reached 7.3 months and median overall survival was 14.7 months after a median follow-up of 14.7 months, with over 90% of enrolled patients presenting with de novo metastatic disease. The 3 mg/kg dose cohort remains enrolling and may serve as the registrational dose for a Phase III trial, with the company targeting Phase 3 readiness in 2026. Spevatamig leverages a novel mechanism designed to activate innate immune cells against tumors typically resistant to checkpoint inhibitors, and the FDA has granted orphan and Fast Track designations for pancreatic cancer. The ongoing collaboration with Merck for pembrolizumab combinations adds optionality to the development pathway. Watch for maturation of the 3 mg/kg cohort efficacy data and any announcement regarding Phase III trial design or regulatory endpoints.

Phanes Therapeutics clinical trial update

Qualitas Dental Partners Expands Acquisition Capacity to Capture Practice Consolidation Demand in Southern New England Qualitas Dental Partners increased its credit acquisition facilities with Live Oak Bank to support continued practice partnerships across Southern New England, responding to strong interest from dental practices seeking alignment with the company's doctor-led partnership model. The company has recently invested in expanding existing practices and recruiting additional dentists to the region, positioning itself as an alternative to traditional dental consolidation plays that often prioritize scale over clinical autonomy. Live Oak Bank's continued partnership signals confidence in the business model and growth trajectory, while the expanded capacity reflects competitive positioning against larger consolidation players in the region. The announcement aligns with broader healthcare services consolidation trends, particularly in dental where group practice models continue gaining share. Financial terms of the expanded facilities were not disclosed, and no specific timeline for deployment or acquisition targets was provided.

Qualitas Dental Partners partnership update

Watchlist

• Erbe USA Cryoprobe Class I Recall: FDA classified a recall for Flexible Cryoprobes due to devices rupturing during activation, with five serious injuries reported including potential hearing damage. Affected part numbers include 20402-401, 20402-410, and 20402-411. Healthcare facilities should audit inventory and remove affected devices, as the rupture risk could cause procedural complications. [link]
• FDA Approves AbbVie's DECNUPAZ for BPDCN: Pivekimab sunirine-pvzy became the first and only ADC approved for blastic plasmacytoid dendritic cell neoplasm, demonstrating a 69.7% composite complete response rate in newly diagnosed patients with a median duration of response of 9.7 months. The CD123-targeting ADC carries a boxed warning for hepatotoxicity and enables outpatient treatment initiation for this ultra-rare aggressive blood cancer. [link]
• Jazz's Ziihera Phase III Results Published in NEJM: Zanidatamab-hrii combinations significantly improved survival versus trastuzumab plus chemotherapy in first-line HER2-positive gastroesophageal adenocarcinoma, with median overall survival of 26.4 months versus 19.2 months (HR 0.72) and median progression-free survival of 12.4 months versus 8.1 months (HR 0.63-0.65). Notably, efficacy extended across PD-L1 positive and negative subgroups, and data were submitted to NCCN for guideline inclusion. [link]
• Virginia Governor Signs Kratom Regulation Law: HB360 bans 7-hydroxymitragynine products and requires mandatory addiction warnings on Kratom, effective July 1, 2026. The law passed with overwhelming bipartisan margins and represents a regulatory shift treating Kratom as an opioid-like substance requiring pharmacy-level controls, potentially establishing precedent for other states. [link]
• Ribo Submits Phase 2 CTA to EMA for siRNA CAD Candidate: RBD1119 targets coronary artery disease as part of Ribo's anticoagulation/thromboembolic pipeline, with the company citing residual thrombotic risk and bleeding complications with current standard-of-care therapies as the unmet need. Dr. Anders Gabrielsen, Chief Medical Officer, framed the submission as advancing RNA-based therapies toward improved benefit-risk profiles. [link]